Brief: Enliven Therapeutics Announces Positive Data Update From Phase 1 Clinical Trial Of ELVN-001 In Chronic Myeloid Leukemia
28/09/2024 14:36
Sept 28 (Reuters) - Enliven Therapeutics Inc ELVN.O :
* ENLIVEN THERAPEUTICS ANNOUNCES POSITIVE DATA UPDATE FROM
PHASE 1
CLINICAL TRIAL OF ELVN-001 IN CHRONIC MYELOID LEUKEMIA
* ENLIVEN THERAPEUTICS INC - ELVN-001 WELL-TOLERATED WITH NO
DOSE
REDUCTIONS IN 39 PATIENTS
Source text for Eikon: ID:nGNX1XJ616
Further company coverage: ELVN.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Enliven Therapeutics
See all newsBrief: Enliven Therapeutics Appoints Kristine Ball To Board Of Directors Ahead Of Planned Phase 3 Trial Initiation This Year
US RESEARCH ROUNDUP-Amrize, Dexcom, Lennar
U.S. RESEARCH ROUNDUP- Berkshire Hathaway, Exxon Mobil, Honeywell Technologies
U.S. RESEARCH ROUNDUP-Caterpillar, Eli Lilly, McKesson
Enliven Therapeutics Q2 net loss widens on higher expenses